Last reviewed · How we verify

NIMBEX

Assistance Publique Hopitaux De Marseille · FDA-approved active Small molecule

Nimbex (cisatracurium) is a non-depolarizing neuromuscular blocking agent that competitively inhibits acetylcholine at the neuromuscular junction.

Nimbex (cisatracurium) is a non-depolarizing neuromuscular blocking agent that competitively inhibits acetylcholine at the neuromuscular junction to produce skeletal muscle paralysis. Used for Skeletal muscle relaxation during anesthesia for intubation and surgery, Mechanical ventilation in intensive care settings.

At a glance

Generic nameNIMBEX
SponsorAssistance Publique Hopitaux De Marseille
Drug classNon-depolarizing neuromuscular blocking agent
TargetNicotinic acetylcholine receptor
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Cisatracurium binds to nicotinic acetylcholine receptors at the motor end plate, preventing acetylcholine from binding and thereby blocking neuromuscular transmission. This results in muscle paralysis used during anesthesia and mechanical ventilation. It undergoes Hofmann elimination and ester hydrolysis, making it suitable for patients with hepatic or renal impairment.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results